37 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
6 Dec 22
Regulation FD Disclosure
8:01am
under Special Protocol Assessment 12
CAN-2409 is generally well tolerated in ongoing phase 2b clinical trial in patients with prostate cancer … ) 3 In treatment window: Post-enrollment but not yet reached 12-week assessment 4 Adverse events: Empyema grade 3 possibly related to study drug
8-K
EX-99.1
CADL
Candel Therapeutics Inc
25 Apr 24
Candel Therapeutics Announces Upcoming Presentations
8:30am
phase 3 clinical trial in prostate cancer is being conducted under a Special Protocol Assessment by FDA. The FDA has also granted Orphan Drug Designation
8-K
EX-99.1
CADL
Candel Therapeutics Inc
26 May 22
Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer
5:36pm
assessment due to an irradiated lesion; the patient still showed an absence of disease progression for more than 6 months.
Two of the three patients
8-K
EX-99.1
CADL
Candel Therapeutics Inc
12 Dec 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Pancreatic Cancer
8:30am
in prostate cancer is being conducted under a Special Protocol Assessment by FDA.
About Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic cancer
8-K
EX-99.1
CADL
Candel Therapeutics Inc
11 Apr 24
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
9:00am
Protocol Assessment by FDA.
About Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic cancer is a highly lethal form of cancer, and it is the fourth
8-K
EX-99.1
ixo7poit5 ksa
4 Apr 24
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:30am
8-K
EX-99.1
23tqc8xngw3 ualyr3
19 May 23
Regulation FD Disclosure
9:15am
10-K
xmyq2nei
29 Mar 22
Annual report
8:46am
S-3
ptdhb
5 Aug 22
Shelf registration
5:08pm
S-1/A
ups095j hlhv3lwav
16 Jul 21
IPO registration (amended)
6:07am
S-1
2zmk5lob1pzu43 5f
25 Jun 21
IPO registration
5:28pm
DRS/A
liwf67
31 Mar 21
Draft registration statement (amended)
12:00am
424B4
glqgx8 96ueynrk
28 Jul 21
Prospectus supplement with pricing info
4:02pm
DEF 14A
vs3ojh uf79
2 Sep 22
Definitive proxy
8:30am